ArticleJournal of the Endocrine Society2023
Genetically Determined Metabolites in Graves Disease: Insight From a Mendelian Randomization Study.
Article in Journal of the Endocrine Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Autoimmune thyroid disease and human health: a systematic review of Mendelian randomization studies.Frontiers in immunology · 2025Pooled it
- N-phenethylacetamide, diaminopimelic acid, and Gly-Val as high-performance serum biomarkers for diagnosing untreated Graves' disease: an LC-MS-based metabolomics study.Frontiers in endocrinology · 2025Article
- Genetically Determined Metabolites in Graves Disease: Insight From a Mendelian Randomization Study.Journal of the Endocrine Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Graves disease (GD) is a prevalent autoimmune disorder with a complex etiology. The association between serum metabolites and GD remains partially understood. Objective: This study aimed to elucidate the causal connections between serum metabolites and predisposition to GD, examining potential genetic interplay. Methods: A 1-sample Mendelian randomization (MR) study was conducted on the GD analysis that included 2836 cases and 374 441 controls. We utilized genome-wide association study summary data from the FinnGen project, analyzing the causal impact of 486 serum metabolites on GD. Approaches used were the inverse variance weighted methodology, Cochran's Q test, MR-Egger regression, MR-PRESSO, Steiger test, and linkage disequilibrium score regression analyses to assess genetic influence on metabolites and GD. Results: 19 metabolites were identified as having a pronounced association with GD risk, of which 10 maintained noteworthy correlations after stringent sensitivity assessments. Three metabolites exhibited significant heritability: kynurenine (OR 3.851, Conclusion: This study unveils pivotal insights into the intricate relationships between serum metabolites and GD risk. By identifying specific risk and protective factors, it opens avenues for more precise disease understanding and management. The findings underline the importance of integrating genomics with metabolomics to fathom the multifaceted nature of GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.